DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

DE

521.35

+1.63%↑

FDX

241.11

+1.75%↑

PAYX

147.15

+1.56%↑

CPRT

49.29

+0.55%↑

HEICO

324

+1.6%↑

Search

Ocugen Inc

Closed

0.94 3.3

Overview

Share price change

24h

Current

Min

0.93

Max

0.95

Key metrics

By Trading Economics

Income

-1.5M

-15M

Sales

717K

1.5M

EPS

-0.05

Profit margin

-1,036.462

Employees

95

EBITDA

-350K

-14M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+559.38% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

93M

297M

Previous open

-2.36

Previous close

0.94

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 Jul 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 Jul 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 Jul 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 Jul 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 Jul 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 Jul 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 Jul 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

559.38% upside

12 Months Forecast

Average 6.33 USD  559.38%

High 8 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.